High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine design

Kaia Palm^{1*#}, Mariliis Jaago^{1,2*}, Annika Rähni^{1,2}, Nadežda Pupina¹, Arno Pihlak¹, Helle Sadam^{1,2}, Annela Avarlaid², Anu Planken³, Margus Planken³, Liina Haring⁴, Eero Vasar^{5,6}, Miljana Baćević⁷, France Lambert⁸, Eija Kalso⁹, Pirkko Pussinen¹⁰, Pentti J. Tienari¹¹, Antti Vaheri¹², Dan Lindholm^{13,14}, Tõnis Timmusk^{1,2} and Amir M Ghaemmamghami^{15#}

¹Protobios Llc, Tallinn, Estonia. Electronic address: kaia@protobios.com

²Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia;

³North Estonia Medical Centre Foundation, Tallinn, Estonia;

⁴Institute of Clinical Medicine, University of Tartu, Psychiatry Clinic of Tartu University Hospital, Estonia;

⁵Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia;

⁶Center of Excellence for Genomics and Translational Medicine, University of Tartu, Tartu, Estonia;

⁷Dental Biomaterial Research Unit (d-BRU), Faculty of Medicine, University of Liege, Liege, Belgium;

⁸Department of Periodontology and Oral Surgery, Faculty of Medicine, University of Liege, Belgium;

⁹Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and Department of Pharmacology and SleepWell Research Programme, University of Helsinki, Helsinki, Finland;

¹⁰Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;

¹¹Department of Neurology, Neurocenter, Helsinki University Hospital, and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;

¹²Department of Virology, Medicum, University of Helsinki, Finland;

¹³Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland;

¹⁴Minerva Foundation Institute for Medical Research, Helsinki, Finland;

¹⁵Immunology and Immuno-Bioengineering Group, School of Life Science, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom. Electronic address: Amir.Ghaemmamghami@nottingham.ac.uk

*These authors contributed equally to the work.

Correspondence to Kaia Palm or Amir Ghaemmamghami

Key words: SARS-CoV-2, immunoprfiling, antibody, seroreactivity, COVID-19, antigenic sin

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Little is known about the quality of polyclonal antibody responses in COVID-19 patients, and how it correlates with disease severity or patients' prior exposure to other pathogens. The whole polyclonal antibody repertoire in a retrospective cohort of 538 individuals was mapped against SARS-CoV-2 spike (S) glycoprotein, the main target of antibody immune responses in SARS-CoV-2 infection. Bioinformatic predictions identified 15 major B cell epitopes for S of SARS-CoV-2. Several epitopes localised in RBD of S including those spanning the ACE2-binding site, the highly conserved cryptic epitope of the neutralizing antibody of SARS-CoV, and fusion/entry domains of HR1 and HR2 of S protein of SARS-CoV-2. Intriguingly, some of these epitopes have cross-reactivity to antigens of common pathogens, potentially affecting SARS-CoV-2 infection outcome. High level of anti-Spike SARS-CoV-2 seroreactivity in populations with no history of exposure to SARS-CoV-2 is of clinical relevance and could underpin better understanding of COVID-19 pathophysiology in different populations and provide a blueprint for design of effective vaccines and developing better strategies for antibody testing.

Introduction

COVID-19 pandemic has caused unprecedented health and economic challenges. A large proportion of people infected by SARS-CoV-2 can be asymptomatic¹, whilst in those with symptoms, the disease can cause a spectrum of clinical manifestations from mild upper respiratory tract illness to cytokine storm and severe pneumonia leading to respiratory failure and death². Older age and a number of co-morbidities (e.g. diabetes, cardiovascular diseases)²⁻⁷ have been associated with the development of more severe disease however the underlying mechanisms of poor clinical outcome have remained elusive. Different patterns of immune response in COVID-19 patients are linked both to full recovery (e.g. emergence of antibody secreting cells and SARS-CoV-2 binding antibodies) and to poor clinical outcome (immune dysregulation and prolonged inflammation)⁸ and death. However, the factors driving development of beneficiary versus harmful immune responses are unclear. One of the key features of the human immune system is its memory. First exposure to many of the common human viruses usually occurs during childhood or adolescence that shapes our immune memory and the immune response to self and environmental antigens throughout life^{9,10}. The immune system's response to a new pathogen can be influenced by its memory of the response to a variant of that pathogen or a cross-reactive antigen. This is also known as 'original antigenic sin' (OAS)¹¹, which could lead to either better protection against infection, or to a higher susceptibility and poor clinical outcome. This phenomenon

is probably best shown in the context of many viral infections such as influenza and influenza vaccines¹²⁻¹⁴.

In this study, we investigated the presence of seroreactivity to SARS-CoV-2 major antigenic epitopes of spike (S) glycoprotein^{15,16} using a retrospective cohort of pre SARS-CoV2 patients (**Table 1**). Serum samples from different individuals with varied disease background, with a potential link to COVID-19 severity^{2,4-7}, and healthy controls collected between 2011-2019 (see **Methods**) were used to investigate the existence of immunoreactivity against SARS-CoV-2 main antigenic epitopes using Mimotope-variation analysis (MVA) (**Methods** and **Supplementary Figure 1**).

Results and Discussion

The more abundant and shared peptide antigens of MVA immunoprofiles were clustered into core sequences (motifs) either via group-discriminatory identification (FEP and FEP_HC, SZ and SZ_HC, MS) or non-discriminatory selection (PD-CAD, MI and MI_HC, T2D, BC). Altogether, a set of 22,949 motif sequences were selected, representing the most abundant and common antibody immune response features across age, gender, and different clinical backgrounds (**Supplementary Information**).

Using the data from more prominent immunoprofile features from 538 serum samples, we predicted 15 epitopes within S that were specifically immunodominant (**Figure 1** and **Supplementary Table 1**). Using simulated random alignment data, epitopes predicted by MVA were statistically significant ($p < 0.05$) (**Figure 1**). Of these, 10 overlapped with the 29 CoV-2 reactive B cell epitopes¹⁷ with average overlap of 60.1% per epitope, due to shorter length of MVA-predicted epitopes. Four of the epitopes (Epitopes 4, 5, 6, and 7, (Ep.4, Ep.5, Ep.6, Ep.7)) were mapped to the receptor binding domain (RBD), spanning amino acids 319 to 542 of S that is a crucial antigenic attachment region for binding with ACE2¹⁸ (the main receptor for host cell infection) (**Figure 1** and **Supplementary Figure 2**). In addition to positioning within the RBD, Ep.5 and Ep.6 overlap with the key amino acids important for binding to human ACE2¹⁸ (**Figure 1**). Ep.4 and Ep.7 overlap with either the N- or C-terminal region, respectively, of the discontinuous epitope described for CR3022, a neutralizing antibody previously isolated from a convalescent SARS-CoV patient which can also bind the RBD of SARS-CoV-2¹⁸ (**Figure 1**). Interestingly, Ep.4 includes P384 residue, and Ep.7 contains H519 (mis valkude järjestuse järgi aminohappe pos on määratud?) which are non-conserved between SARS-CoV and CoV-2 (**Supplementary Fig 2**). Ep.14 co-localizes with the fusion/entry domains of HR1 and Ep.15 is directly N-terminal to HR2 of S SARS-CoV-

2¹⁹ (Figure 1).

Figure 1. MVA predictions of epitopes for antibodies with known and novel specificity to S glycoprotein of SARS-CoV-2.

Sequence alignment histograms for potential antibody-specificity against S reveals prominent epitopes with alignment loads above the 95% percentile. 22,949 unique core motif sequences (of 1,380,000 distinct peptide sequences), representing top most abundant and shared immune response, were screened for sequence similarity with SARS-CoV-2 Spike glycoprotein (P0DTC2) by alignment analysis. The specific/random ratio is the alignment of motifs matching with ≥ 4 amino acid positions (specific) in proportion to shuffled-sequence motifs (random). The ratio is calculated per each amino acid position on the primary sequence of S (*left y-axis, black line-graph*). Using simulated alignment distribution, 14 of predicted epitopes Ep.1 to Ep.15 were statistically significant (p -value < 0.05) (Ep.4 with p -value < 0.06). Of aligned motifs, 111 were found with exact-matching amino acid positions. The exact-matching motifs were counted for each amino acid position on primary sequence of S (*right y-axis, royal blue line-graph*). IEDB, regions in IEDB that were predicted as B cell epitopes of S of SARS Cov-2¹⁷. MVA-predicted epitopes marked with *red empty boxes* differ from IEDB-marked epitopes. MVA-predicted epitopes marked with *rose gold empty boxes* overlap with IEDB-marked epitopes. ACE2, amino acid positions important for binding to human ACE2, the receptor for host cell infection¹⁸. CR3022, amino acid positions important for binding of CR3022 anti-SARS-CoV-2 Spike RBD antibody¹⁸. S glycoprotein domains are visualized schematically, adapted from Wrapp et al.¹⁵ with additional information about RBD from Yuan et al.¹⁸. SS – signal peptide (1-12); NTD – N-terminal domain (13-303); RBD – receptor binding domain (319-542); S1/S2 – S1 subunit end and S2 start site (683-686); S2' – S2' protease cleavage site (815-816); FP – fusion peptide (816-833); HR1 – heptad repeat 1 (908-985); CH – central helix (986-1035); CD – connector domain (1076-1141); HR2 – heptad repeat 2 (1163-1202); TM – transmembrane domain (1214-1234); RU – relative unit, count of motifs with exact identity to SARS-CoV-2 S in each amino acid position.

Next, we characterized the immunoreactivity patterns of the predicted epitopes of S across the whole cohort divided by different comorbidities and age (**Figure 2**). All examined epitopes, Ep.1 to Ep.15 exhibited immunoreactivity profiles that were highly individual-specific (**Figure 2A**). Exploratory data analysis revealed associations between immunoreactivity profiles and subject age, gender or clinical backgrounds (**Supplementary Table 2**), warranting more focused analysis.

Figure 2. Immunoprofiles of peptide antigens with high similarity to the primary sequence of SARS-CoV-2 Spike glycoprotein (P0DTC2) across the study cohort (n=538). 22,949 unique core motif sequences (of 1,380,000 unique peptides), representing top most abundant and shared immune response, were screened for sequence similarity with SARS-CoV-2 spike glycoprotein P0DTC2 by alignment analysis. Of these, 111 were found across the primary sequence of Spike glycoprotein. **A** | The abundance of immunoprofile peptides containing the 111 motifs (*in rows*) was extracted for 538 samples, of which 524 were with known age (*in columns*) with varying clinical background, gender and age. The abundance of motif-containing peptides across subjects is visualized in log scale as intensity plot. The order of motifs is from N-terminal (down) to C-terminal (up) orientation on S, with predicted epitopes with spanning amino acids indicated on the left, where applicable. The result suggests high levels of individuality across predicted S-associated immunoprofile features. Peptide abundance (*abundance*) is color-coded in $\log_{10}$. Group abbreviations: Controls – healthy controls (HC groups), HC-MI, HC-CAD, HC-FEP, HC-SZ groups. Cases - MS – multiple sclerosis; BC – breast cancer; T2D – type 2 diabetes; MI – myocardial infarction; CAD – coronary artery disease; FEP – first episode psychosis; SZ – schizophrenia. **B** | Focused view at the clustering and abundance of epitope motifs on the receptor binding domain (RBD) of S (18 motifs in rows). Cases (n=186) included BC, T2D, MI, CAD, with matching controls where possible (n=93).

We did not detect any significant differences in neutralizing response (Ep.4 and Ep.7) among subjects older or younger than 61 years old (**Figure 2B** Kruskal-Wallis test, $p>0.05$ and **Supplementary Figure 3**). The abundance of antibodies predicted to interact with Ep.5 was higher among older subjects $61 \leq$ than younger subjects aged 41-60 or ≤ 40 (Mann-Whitney

U, **** $p < 0.0001$) (**Figure 3A**). Intriguingly, Ep.5 is within the RBD of SARS-CoV-2 S protein¹⁸ (**Figure 1**) and contains overlapping key amino acids important for binding to ACE2 (**Supplementary Figure 2**). In Ep.5, the amino acids important for binding ACE2 are 100% conserved between SARS-CoV and CoV-2, with the exception of SARS-CoV-2 F456 → SARS-CoV L443 transformation not targeted by aligned motifs (**Supplementary Figure 2**). Response against Ep.1 and Ep.8 of S was also found higher among older subjects aged $61 \leq$ (Mann-Whitney U, **** $p < 0.0001$) (**Figure 3A**). Response against Ep.6 of S was higher among younger subjects aged ≤ 40 or $41-60$ than in subjects aged $61 \leq$ (Mann-Whitney U, **** $p < 0.0001$) (**Figure 3B**).

Antibody response against Ep.12 and Ep.14 of S2 of S was also statistically higher in younger subjects (Mann-Whitney U, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$) (**Figure 3B**), whereas response to remaining predicted S epitopes was not substantially different across age groups (**Supplementary Figure 3**).

Figure 3. Age-associated differential antibody response to predicted epitopes of S RBD. The abundance of antibodies potentially specifically targeting S was assessed across age groups of 524 studied subjects. **A** | Antibody response to epitopes Ep.1, Ep.5 and Ep.8 of S was significantly higher in subjects aged $61 \leq$ than in younger age groups. Pearson correlation for Ep.5 response (in log) and subject age was $R = 0.20$ ($p = 6.6 \times 10^{-6}$, 95% CI (0.11, 0.28)), suggesting a weak positive correlation. Pearson correlation coefficient between subject age and Ep.1 response was $R = 0.17$ ($p = 1.3 \times 10^{-4}$, 95% CI (0.08, 0.25)) and between anti-Ep.8 response $R = 0.17$ ($p = 6.2 \times 10^{-5}$, 95% CI (0.09, 0.26)). Relative antibody response is assessed as abundance of peptide antigens containing epitope motif (y-axis) (**Figure 1**). Group sizes: ≤ 40 ($n = 186$), $41 \leq x \leq 60$ ($n = 188$), $61 \leq$ ($n = 150$). **B** | Antibody response to epitopes Ep.6, Ep.12 and Ep.14 of S was significantly higher among younger ≤ 40 or $41-$

60 than in older subjects aged $61 \leq$. Kruskal-Wallis test for multiple group comparison, pair-wise comparison with Mann-Whitney U test, ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Next we analysed frequency of antibody responses to different epitopes in subjects with hypertension (HT), cardiovascular diseases (CVD) and subjects who smoked cigarettes. Ep.2, Ep.5, Ep.8, Ep.9, Ep.11, and Ep.13 were statistically (Mann-Whitney U) higher among subjects with HT (**Figure 4** and **Supplementary Figure 4** and **Figure 5**). An interesting difference was observed in male and female subjects with HT (**Figure 4** and **Supplementary Figure 6**). The higher response to Ep.5 of S RBD was preferentially in males with HT (Mann-Whitney U, * $p < 0.05$, **Figure 4**), whereas the HT-associated higher response to Ep.8 was common to both sexes, however the male subjects with HT were found to have higher response to Ep.8 compared to female subjects with HT (**Figure 4**). On the other hand, males with coronary artery disease (CAD) or MI showed statistically higher response to Ep.3 of S compared to females, whereas females with either CAD or MI showed significantly reduced response against Ep.6 of S compared to males (or healthy controls, **Figure 4**, **Supplementary Figure 7**). Cigarette smoking is a risk factor for both HT and CVD. However, some epidemiological observations suggest daily cigarette smokers have a lower probability of developing severe COVID-19 than the general population^{20,21}. In the clinical cohort of CAD ($n=96$), predicted immune response to both Ep.6 and Ep.13 of S was identified as significantly higher among cigarette smokers than in non-smokers (**Figure 4**).

Figure 4. Specific higher response against epitopes of S was associated with hypertension (HT), cardiovascular diseases (CVD) and cigarette smokers. Statistical analysis identified anti-S response against epitopes of Ep.5 and Ep.8 as significantly higher in subjects with HT (n=112) than no-HT (n=81, **Supplementary Figure 5**). However, gender-based analysis revealed high Ep.5 response as male-HT specific and anti-Ep.8 response as higher in males with HT than in females with HT (**Supplementary Figure 6**). Relative antibody response is assessed as abundance of peptide antigens containing epitope motif (y-axis) (**Figure 1**). Group sizes: noHT, M (n=71), noHT, F (n=43), HT, M (n=48), HT, F (n=33). Male subjects with CAD or MI had higher response against Ep.3 of S than female subjects with CAD or MI (or healthy controls) (**Supplementary Figure 7**). Female subjects with either CAD or MI showed reduced response against S Ep.6 than male subjects with CAD/MI (or healthy controls). Group sizes: HC, M (n=40), HC, F (n=49), Case, M (n=79), Case, F (n=27). Within the PD-CAD clinical cohort (n=96), subjects who were active cigarette smokers were identified as having higher response against predicted S Ep.6 or Ep.13 than non-smokers. Group sizes: Non-smokers ("No") (n=49), previous history of smoking ("History") (n=33), active cigarette smokers ("Smoking") (n=14). Mann-Whitney U test, ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. M, male, F female.

Taken together, our analysis predicted Ep.1 and Ep.3 (NTD of S), Ep.5 (RBD of S), Ep.8, and Ep.13 (S2 of S) as Spike epitopes linked to age, HT, CVD and tobacco use, all of which are confounding factors of COVID-19 severity. Although associated with tobacco use and gender-related cardiovascular condition, notably higher response to Ep.6 was correlated with younger age.

The observation of shared high immunogenicity of predicted epitopes of S suggested that regions in S contained evolutionarily and/or structurally related immunogenic targets. B cell-specific response potentially able to cross-react with S of SARS-CoV-2 might arise from exposure to other (beta-) coronaviruses commonly infecting humans²², or common human pathogen not evolutionarily related to coronaviruses but with protein structural similarity^{14,23}. Sequence alignment analysis with common human beta-coronaviruses and across the human viral pathogenome (<https://www.uniprot.org/help/uniprotkb>) revealed substantial sequence similarity conservation of SARS-CoV-2 epitopes with other endemic CoVs (i.e. CoVs OC43 and HKU1) and other common pathogenic antigens, most notably human cytomegalovirus and human herpesvirus 6B (**Supplementary Figure 8, Table 3**), offering a mechanism for pathogenic cross-reactive mimicry. Exposure to many of the common human viruses usually occurs during childhood or adolescence that shapes our immune memory and modulates the subsequent response to self and environmental antigens later in life^{9,10}.

The cell biology of SARS-CoV-2 is so far less known than that of other coronaviruses. Emerging evidence show that binding of SARS-CoV-2 to ACE2 on the surface of target cells such as lung endothelium is essential for viral infectivity. Our data reveal major epitope-specific responses to SARS-CoV-2 in an infection naïve population. Most interestingly, some of these antibodies overlap with crucial antigenic attachment region of SARS-CoV-2 S binding with ACE2, some with that of the neutralizing antibody (CR3022) of SARS-CoV-2, and some with cell fusion/entry domains HR1 and HR2. Our data also highlight the age-linked differential patterns of immune response to S, with individuals aged >60 being more apt to (suboptimal) antibody responses potentially affecting ACE2- S protein RBD of SARS-CoV-2 interactions (Ep.6, **Figure 1** and **3**).

These findings indicate that it is difficult to distinguish exposure to SARS-CoV-2 from other CoVs and common pathogens in serological studies using SARS-CoV-2 S as antigen. This implies that epitope-specific diagnostic assays will need to be designed. Our data further lends credence to the view that immunological memory covers families of antigens rather than a particular member only involved in the primary response, causing a rapid anamnestic response, at the expense of specificity^{24,25}. These results also underscore the possibility of antigenic sin, shaping the immune response to SARS-CoV-2, which in turn could influence disease progression and the clinical outcome of COVID-19¹⁴.

Methods

Clinical cohorts

To investigate pre-existing immunoreactivity able to cross-react with the SARS-CoV-2 main antigenic epitopes on S protein, we examined the antibody immune profiles of several relevant clinical cohorts (**Table 1**). Blood samples were collected prior to SARS-CoV-2 emergence (2011 to September 2019) under local ethical approvals.

Table 1. Descriptions of clinical cohorts.

No	Cohort (abbreviation)	Diagnosis group	Group size (n)	Gender	Age (mean $\pm$ SD), years	Ethnicity
Cardiovascular diseases (with comorbidities including obesity, hypertension, diabetes)						
1.	Periodontitis and coronary artery disease (PD-CAD)	No-CAD	32	17M/15F	60.2	Finnish
		Stable-CAD	32	26M/6F	64.3	
		ACS	32	24M/8F	61.3	

2.	Myocardial infarction (MI)	HC	50	20M/30F	40.8	Estonian
		MI	50	29M/13F/8NA	66.8 (based on 40 individuals); 10 NA	Estonian
3.	T2D and foot ulcer	T2D	25	21M/4F	69.0 ± 8.7	Belgian
Diseases with autoimmune component						
4.	Multiple sclerosis (MS)	MS	20	4M/16F	32.3 ± 7.8	Finnish
Cancer						
6.	Breast cancer (BC)	Non-NP	30	0M/30F	57.4 ± 7.8	Finnish
		NP	27	0M/27F	53.9 ± 6.1	Finnish
Psychiatric diseases						
7.	First episode psychosis (FEP)	HC	30	15M/15F	24.0 ± 6.1	Estonian
		FEP	30	15M/12F/3 NA	26.0 ± 4.9 (based on 27 individuals); 3 NA	Estonian
8.	Schizophrenia (SZ)	HC	30	12M/18F	42.1 ± 18.2	Finnish
		SZ	30	12M/18F	41.9 ± 18.4	Finnish

ACS – acute coronary syndrome; NP – neuropathic pain; T2D – type II diabetes with impaired wound healing; HC – healthy control; M – male; F – female; NA – not available

Mimotope-variation analysis

For qualitative and quantitative characterization of humoral immune response from blood samples, we used an in-house developed mimotope-variation analysis (MVA) method as described previously²⁶. In brief, a random 12-mer peptide phage library (Ph.D.-12, NEB, UK) was used according to the manufacturer's protocol. Two µl of serum samples were incubated with 2.5µl library (~5 × 10¹¹ phage particles) and immunoglobulin G (IgG) fraction was recovered by using protein G-coated magnetic beads (Thermo Fisher Scientific). Captured phage DNA was analysed by using next generation sequencing (Illumina HiSeq, 50-bp single end reads) with barcoded primers for sample multiplexing. To evaluate the reproducibility of proteomics data, we compared peptide abundance in two replicates using Pearson correlation coefficient, which was 0.985 (p<0.0001) (**Supplementary Figure 1**).

Data analysis

Peptides in a sample dataset were trimmed to 3 million reads (RPM units). SPEXS2

exhaustive pattern search algorithm²⁶ was used to cluster similar peptides and reveal recognition patterns (epitope motifs) that would be enriched in studied peptide sets (Documentation: <https://github.com/egonelbre/spexs2>). The identification of core motif sequences was either performed discriminatorily, where selected peptide sets were studied for enrichment compared to a control group, or non-discriminatorily, where enrichment was identified compared to a random-generated peptide set (hypothesis-free). In brief, for each clinical group, 100,000s of distinct peptide antigens were used as input, from which 1000s of distinct core epitope motifs were identified with SPEXS2 algorithm. The motifs were collected together to generate a broad screening set of 22,949 motifs, representing different age groups, genders, and clinical background. The 22,949 motif sequences were aligned to primary sequence of SARS-CoV-2 Spike glycoprotein (S) (UniProtKB accession P0DTC2). A detailed description for clustering workflow is in **Supplementary Information**.

Sequence alignment

SARS-CoV-2 proteome and Spike (S) glycoprotein (P0DTC2) were obtained from www.viralzone.expasy.org/8996 (date accessed 25.03.2020). To predict immunogenic regions on S, in-house built custom algorithms were used for sequence alignment. Primary sequence of S was scanned with 22,949 distinct motifs with criterium of ≥ 4 exact-matching amino acid positions. Random reference profile was generated by scanning with shuffled-sequence motifs (≥ 4 exact positions). Random alignment distribution was simulated with 3 independent alignments with shuffled motifs. Specific alignments above 0.95 percentile of simulated distribution were statistically significant ($p < 0.05$). Alignment profiles were visualized using custom Excel VBA scripts and MS Office Excel.

Predicted B cell epitopes for the SARS-CoV-2 virus were published by Grifoni and colleagues¹⁷. Amino acids on Spike glycoprotein (S) of SARS-CoV-2 important for binding to human ACE2 were recently reported by different groups and anti-Spike RBD neutralizing antibody CR3022 discontinuous epitope were reported by Yuan and colleagues¹⁸. Domains of S were accessed from recently published data^{15,18}.

SARS-CoV S glycoprotein primary sequence (P59594) was accessed from UniProtKB (date accessed 25.03.2020). To assess conservation of S from SARS-CoV-2, SARS-CoV, OC43 and HKU1 sequence alignment was performed with Clustal Omega tool (version 1.2.4) with default settings (<https://www.ebi.ac.uk/Tools/msa/clustalo/>).

Reference proteins for SARS-CoV-2 Spike glycoprotein (S) alignment with common human

pathogens were obtained from UniProtKB with keywords “human” + “virus” (date accessed: 16.12.2019). The primary sequences of reference proteins, were first scanned with 111 SARS-CoV-2 S protein motifs with the criterium of an exact match. The reference proteins, which gave a match with S protein motif alignment, were consequently scanned with predicted S protein epitope sequences with the criteria of ≥ 5 exact-matching amino acid positions. Alignment procedures were carried out using custom Excel VBA scripts and MS Office Excel. Known epitopes of reference proteins that showed potential for cross-reactions with SARS-CoV-2 S protein were obtained from Immune Epitope Database’s full epitope list (epitope_full_v3.zip) (accessed 29.04.2020).

Statistical analysis

All statistical analyses (ANOVA, t-Test, correlation analyses, ROC analysis) were done using R statistical programming language and RStudio environment (RStudio Team, 2015; R Core Team, 2017). Boxplot graphs were produced and visualized using packages “reshape2”, “dplyr”, and “ggplot2” 2020 versions ²⁷. For visualization of peptide abundance across the sample set, peptide frequencies were converted to base 10 logarithmic values and intensity plots were graphed in MS Office Excel.

Data Availability

The data that support the findings of this study are available on request from the corresponding author (KP). The data are not publicly available due to containing information that could compromise research participant privacy/consent. Any materials that can be shared will be released via a material transfer agreement.

Ethics Statement

Immunoprofiling of the samples has been approved by the institutional ethics committees, and all subjects provided written informed consent.

Author Contributions

AR and NP contributed equally to the work as 2nd authors. KP, MJ, AR, NP, and AMG conceived and designed the study. AP, MP, LH, EV, MB, FL, EK, PP, PT, AV and DL collected samples and acquired the clinical data. KP, MJ, AR, NP, AP, HS, AA and AMG analyzed and interpreted the data. EV, PT, DL, TT and KP supervised the study. KP and

AMG drafted the manuscript. All authors revised and approved the final manuscript for submission.

Funding

This study was supported by institutional research funding grants of Protobios (5.1-4/20/170, and PRG573) from the Estonian Research Council and H2020-MSCA-RISE-2016 (EU734791) from the European Union, Helsinki University Hospital grants, Mary and Georg C. Ehrnroth Foundation, Finnish Eye Foundation. KP, AA, and TT were partially supported by the institutional research grant IUT19-18 of TUT from the Estonian Research Council. This project has also received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement 760921 (PANBioRA).

Acknowledgments

Mirjam Luhakooder, Helen Verev, Susan Pihelgas and Maila Rähn are thanked for excellent technical assistance.

References

- 1 Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*, doi:10.1126/science.abb3221 (2020).
- 2 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062, doi:10.1016/S0140-6736(20)30566-3 (2020).
- 3 Guan, W. J. *et al.* Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J*, doi:10.1183/13993003.00547-2020 (2020).
- 4 Garg, S. *et al.* Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 458-464, doi:10.15585/mmwr.mm6915e3 (2020).
- 5 Grasselli, G. *et al.* Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*, doi:10.1001/jama.2020.5394 (2020).
- 6 Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*, doi:10.1016/S2213-2600(20)30079-5 (2020).
- 7 Qin, C. *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis*, doi:10.1093/cid/ciaa248 (2020).
- 8 Thevarajan, I. *et al.* Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nature Medicine*, doi:10.1038/s41591-020-0819-2 (2020).
- 9 Rouse, B. T. & Sehrawat, S. Immunity and immunopathology to viruses: what decides the outcome? *Nat Rev Immunol* **10**, 514-526, doi:10.1038/nri2802 (2010).

- 10 White, D. W., Suzanne Beard, R. & Barton, E. S. Immune modulation during latent herpesvirus infection. *Immunol Rev* **245**, 189-208, doi:10.1111/j.1600-065X.2011.01074.x (2012).
- 11 Vatti, A. *et al.* Original antigenic sin: A comprehensive review. *J Autoimmun* **83**, 12-21, doi:10.1016/j.jaut.2017.04.008 (2017).
- 12 Zhang, A., Stacey, H. D., Mullarkey, C. E. & Miller, M. S. Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. *J Immunol* **202**, 335-340, doi:10.4049/jimmunol.1801149 (2019).
- 13 Xu, R. *et al.* Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. *Science* **328**, 357-360, doi:10.1126/science.1186430 (2010).
- 14 Yewdell, J. W. & Santos, J. J. S. Original Antigenic Sin: How Original? How Sinful? *Cold Spring Harb Perspect Med*, doi:10.1101/cshperspect.a038786 (2020).
- 15 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).
- 16 Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*, doi:10.1038/s41591-020-0897-1 (2020).
- 17 Grifoni, A. *et al.* A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host Microbe*, doi:10.1016/j.chom.2020.03.002 (2020).
- 18 Yuan, M. *et al.* A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. *Science*, doi:10.1126/science.abb7269 (2020).
- 19 Xia, S. *et al.* Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell Mol Immunol*, doi:10.1038/s41423-020-0374-2 (2020).
- 20 Garufi, G., Carbognin, L., Orlandi, A., Tortora, G. & Bria, E. Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence. *Eur J Intern Med*, doi:10.1016/j.ejim.2020.04.042 (2020).
- 21 Propper, R. E. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection? *Nicotine Tob Res*, doi:10.1093/ntr/ntaa073 (2020).
- 22 Meyer, B., Drosten, C. & Muller, M. A. Serological assays for emerging coronaviruses: challenges and pitfalls. *Virus Res* **194**, 175-183, doi:10.1016/j.virusres.2014.03.018 (2014).
- 23 Kanduc, D. & Shoenfeld, Y. Human Papillomavirus Epitope Mimicry and Autoimmunity: The Molecular Truth of Peptide Sharing. *Pathobiology* **86**, 285-295, doi:10.1159/000502889 (2019).
- 24 Monto, A. S., Malosh, R. E., Petrie, J. G. & Martin, E. T. The Doctrine of Original Antigenic Sin: Separating Good From Evil. *J Infect Dis* **215**, 1782-1788, doi:10.1093/infdis/jix173 (2017).
- 25 Netea, M. G. *et al.* Trained immunity: A program of innate immune memory in health and disease. *Science* **352**, aaf1098, doi:10.1126/science.aaf1098 (2016).
- 26 Sadam, H. *et al.* Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. *EBioMedicine* **29**, 47-59, doi:10.1016/j.ebiom.2018.01.043 (2018).
- 27 Wickham, H. *Ggplot2 : elegant graphics for data analysis*. (Springer, 2009).